Access to Evidence-Based Statins in Low-Cost Generic Drug Programs

Cynthia A Jackevicius¹, Katie Choi², Harlan M Krumholz²

• ¹From the Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA (C.A.J., K.C.); Institute for Clinical Evaluative Sciences, ON, Toronto, Canada (C.A.J.); Pharmacy Department, Veterans Affairs Greater Los Angeles Healthcare System, CA (C.A.J.); Institute of Health Policy, Management and Evaluation, Faculty of Medicine, University of Toronto, ON, Canada (C.A.J.); Pharmacy Department, University Health Network, Toronto, Canada (C.A.J.); Department of Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT; Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven CT (H.M.K.); Department of Health Policy and Management, New Haven, CT (H.M.K.); and Robert Wood Johnson Foundation Clinical Scholars Program, New Haven, CT (H.M.K.). cjackevicius@westernu.edu.+1